Celltrion Healthcare "Antibody Therapeutics Export Expected to Reach 150 Billion KRW This Month"

Initial Shipment of 150,000 Vials of 'Rekkirona' Dispatched to 9 European Countries

[Asia Economy Reporter Seo So-jung] Celltrion Healthcare announced on the 9th that it has completed the shipment of an initial batch of 150,000 vials to 9 countries with which it signed supply contracts in December, as it is actively concluding supply agreements and shipping the COVID-19 antibody treatment 'Rekkirona' (generic name: Regdanvimab).

Celltrion Healthcare has been negotiating exports of Rekkirona with over 70 countries, and including the 9 countries supplied with the initial batch this time, it has signed supply contracts with 18 countries to date. Including existing supply volumes and additional orders, the volume supplied this month alone is expected to reach approximately 150 billion KRW.

Rekkirona has seen increased product inquiries from various countries due to the enhanced product reliability following the European Commission (EC)'s marketing authorization and the surge in COVID-19 confirmed cases. In particular, additional orders continue from countries where the initial shipments have been completed, and separately, new contract discussions are expanding with countries in Europe, Asia, the Middle East, Latin America, and Oceania.

The company expects that the changing perception of COVID-19 responses in each country will positively impact the expansion of Rekkirona supply. Until now, most countries prioritized expanding COVID-19 vaccination policies, but recently, as the response to variant viruses and severe patients has become more prominent, governments are focusing their efforts on securing treatments. Australia, once called a COVID-free country, has recently seen a steady increase in confirmed cases, highlighting the importance of treatments; as a preemptive measure, it granted provisional registration (conditional approval) for Rekkirona on the 6th (local time).

A Celltrion Healthcare official said, "As additional approvals for Rekkirona continue worldwide following EC approval, we plan to expand supply contracts," adding, "The Celltrion Group will do its best to contribute to overcoming the global COVID-19 pandemic not only through Rekkirona but also by developing treatments such as CT-P63, which has excellent efficacy against variant viruses, and inhalation-type treatments that improve treatment convenience."

This content was produced with the assistance of AI translation services.